Real Estate · Real Estate Investment Trusts

DOC Healthpeak Properties SEC Filings & Insider Trading Activity 2026

company
CIK 765880109 filings
S&P 500

DOC at a glance

Healthpeak Properties (DOC, SEC CIK 765880) filed its latest 10-K annual report on February 3, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 2, 2026 and Form 4 insider filings as recently as November 13, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Healthpeak Properties (DOC) reported revenue of $604.0 million (up 6.2% from FY2024) and net income of $71.3 million. Diluted EPS was $0.10.
  • As of September 30, 2026, 39 institutional investment managers tracked by SignalX reported holding Healthpeak Properties (DOC) shares worth $7.7 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Patadia Ankit B. on November 9, 2026 of 6,115 shares at $20.78 per share.
  • In the last 90 days, DOC insiders reported 0 open-market purchases ($0) and 1 open-market sale ($127K) on Form 4, a net sale of $127K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$604.0M
+6.2% vs prior year
Insiders · 90 days
0 buys · 1 sell
Net −$127K
13F holders
39 funds
$7.7B · −2 vs prior quarter
Latest 8-K
Nov 2, 2026
Item 7.01 · Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Risk Factors

  • U.S. federal policy shifts (NIH funding cuts, drug pricing, tariffs) creating life science tenant funding uncertainty, risking rent payment and expansion
  • Exposure to Medicare/Medicaid funding cuts and Affordable Care Act subsidy expiration impacting tenants in non-expansion states, affecting outpatient medical segment revenues
  • Tariffs and supply chain disruptions raising construction costs and delaying development projects, increasing capital access risk
  • Competition risk from international biotech sectors in China with favorable regulations diverting R&D investment away from U.S. lab tenants
  • Tenant insolvency risk under U.S. Bankruptcy Code limiting lease remedies and delaying rent collections, especially under master leases across multiple properties

Management Discussion & Analysis

  • Revenue from resident fees and services $568M in 2024, up $41M YoY from $527M
  • Adjusted NOI $159.6M in 2024 vs $135.6M in 2023, +17.7% YoY, driven by higher fees and occupancy despite higher expenses
  • Best segment: Merger-Combined Same-Store with 17.7% NOI growth; no explicit worst segment disclosed
  • Operating cash flow $1.25B in 2025, up $181M YoY; investing outflows increased $921M; financing activities provided $136M vs $-941M prior year
  • Capital allocation: $94M in common stock repurchases in 2025; dividends increased to $1.22/share annually; $168M development commitments, $9.8B total debt with recent issuances and repayments
  • Forward outlook: Management expects sufficient liquidity for operations, debt service, distributions, and capital needs; notes risks from credit rating downgrades and market conditions impacting borrowing costs

Business Overview

  • Core business model: Own, operate, develop high-quality U.S. healthcare real estate focused on outpatient medical, lab, and senior housing properties
  • New segment emphasis: Preparation for Janus Living IPO, transferring 34 senior housing communities (10,422 units) into a publicly listed REIT structure under majority ownership
  • Strategic shift: Following merger with Physicians Realty Trust, added 299 outpatient medical buildings, expanding scale and tenant base significantly
  • Quantitative metric: Portfolio grew to 689 properties at 12/31/2025; senior housing includes 34 properties plus acquiring remaining 46.5% of SWF SH JV in Jan 2026
  • Noteworthy fact: Senior housing segment redefined to combine life plan communities with sovereign wealth fund JV, reflecting new reportable segment structure for 2025

AI summary of the DOC 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Quarterly revenue not disclosed; net income $17.1M vs $(117.3)M YoY
  • Operating profitability: Adjusted NOI $384.8M, segment margins not disclosed
  • Best segment senior housing: Adjusted NOI $53.7M, up 27.2% YoY; worst outpatient medical: $184.3M, down 7.0%
  • Operating cash flow $976.4M, up $18.6M; investing outflow $2.58B, financing inflow $1.67B
  • Outlook: cash flows and liquidity adequate for next 12 months; headwinds from elevated rates, inflation, tariffs, and lower lab occupancy

Risk Factors

  • No material changes to risk factors since the December 31, 2025 Form 10-K
  • Carried-forward risks may materially affect business, financial condition, or future results

AI summary of the DOC 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 2, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Exhibit 99.2 contains Healthpeak’s supplemental financial results for the three and nine months ended September 30, 2026
  • Investor focus: quarterly operating metrics and portfolio updates in the supplemental report, available through Healthpeak Investor Relations

Item 2.02: Results of Operations and Financial Condition

  • Q3 and nine-month 2026 financial results released for periods ended September 30, 2026
  • Non-GAAP reconciliations included for Healthpeak and Janus Living, supporting analysis of adjusted operating performance

Item EX-99.1: Item EX-99.1

  • Q3 net income $0.02 per share, versus $(0.17) in 2025, while adjusted FFO declined to $0.44 from $0.46
  • 2026 adjusted FFO guidance increased to $1.76-$1.78 per share, despite earnings guidance decreasing to $0.39-$0.41

Item EX-99.3: Item EX-99.3

  • Exhibit 99.3 provides reconciliations for Healthpeak’s non-GAAP measures for the three and nine months ended September 30, 2026
  • Key investor metrics include Nareit FFO, FFO as Adjusted, Adjusted NOI, same-store cash NOI, leverage and fixed-charge coverage
Filed Aug 4, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Supplemental report covers Healthpeak’s three and six months ended June 30, 2026
  • Exhibit 99.2 contains financial results and related investor information

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results covered three and six months ended June 30, 2026
  • Healthpeak issued the earnings release on August 4, 2026

Item EX-99.10: Item EX-99.10

  • Q2 net income $0.08 per share and adjusted FFO $0.46, with FFO flat year over year
  • 2026 guidance raised: adjusted FFO $1.73-$1.77 per share, midpoint up $0.02

Item EX-99.30: Item EX-99.30

  • Exhibit defines Healthpeak’s non-GAAP metrics for the quarter and six months ended June 30, 2026
  • FFO as Adjusted, Adjusted NOI, and Adjusted EBITDAre are key REIT performance measures alongside GAAP results

Item EX-99.1: Item EX-99.1

  • Q2 revenue rose to $771.6M, while FFO as Adjusted held at $0.46 per share, signaling stable underlying earnings
  • 2026 FFO guidance increased to $1.73-$1.77 per share, with same-store cash NOI guidance raised to 0%-1.5%
Filed May 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q1 2026 results for quarter and three months ended March 31, 2026
  • Press release furnished as Exhibit 99.1, containing the company’s reported financial results

Item 7.01: Regulation FD Disclosure

  • Q1 2026 supplemental report furnished as Exhibit 99.2, covering results for three months ended March 31, 2026
  • Investor materials available through Healthpeak’s Investor Relations website for detailed financial and operating metrics

Item EX-99.1: Item EX-99.1

  • Q1 revenue rose 7% to $753.0M, while net income reached $0.28 per share versus $0.06
  • FFO as Adjusted declined to $0.45 per share from $0.46, highlighting limited underlying earnings growth despite stronger reported net income

AI summaries of DOC 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for DOC

Don't miss the next DOC filing

  • Alerts as it files. A push when DOC files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut DOC, by share count.
  • Ask anything. An AI agent that reads every DOC filing and answers with sources.

DOC alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Thomas John TGNov 13, 2026-
Patadia Ankit B.SellNov 9, 2026$20.78
Lewis Sara GrootwassinkJNov 5, 2026-
Lewis Sara GrootwassinkJNov 5, 2026-
Mabry Adam GFMay 29, 2026$19.15
Patadia Ankit B.AMay 29, 2026$15.46
Patadia Ankit B.FMay 29, 2026$19.15
Moses Kelvin OAMay 29, 2026$15.46

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue$527.4M$568.5M$604.0M
Net Income$306.0M$243.1M$71.3M
Net Margin58.0%42.8%11.8%
Balance Sheet
Total Assets$15.7B$19.9B$20.3B
Equity$6.4B$8.4B$7.5B
ROE4.8%2.9%1.0%
Per Share
EPS$0.56$0.36$0.10
Cash Flow
Operating CF$956.2M$1.1B$1.3B

Source: XBRL data in Healthpeak Properties (DOC)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate DOC share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
DOC shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202639$7.66B
Q2 202641$8.41B
Q1 202640$6.75B
Q4 202537$6.39B
Q3 202540$7.88B
Q2 202540$6.68B
Q1 202539$5.87B
Q4 202435$4.93B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 311 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

DOC filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 13, 2026--
4Nov 9, 2026--
4Nov 5, 2026--
10-QNov 3, 2026Analysis
8-KNov 2, 2026Analysis-
10-QAug 5, 2026Analysis
8-KAug 4, 2026Analysis-
4Jun 2, 2026-
4Jun 2, 2026-
4Jun 2, 2026-
4Jun 2, 2026-
4Jun 2, 2026-
4Jun 2, 2026-
4May 18, 2026-
SC 13GMay 14, 2026-
SC 13GMay 13, 2026-
4May 13, 2026-
4May 7, 2026-
4May 7, 2026-
4May 7, 2026-
4May 7, 2026-
4May 7, 2026-
4May 7, 2026-
4May 7, 2026-
10-QMay 6, 2026Analysis

Related Real Estate companies

All Real Estate →

DOC SEC filings: frequently asked questions

Are DOC insiders buying or selling?

In the last 90 days, Healthpeak Properties (DOC) officers, directors and 10% owners reported no open-market purchases and 1 open-market sale worth $127,070 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold DOC stock?

As of September 30, 2026, the largest Healthpeak Properties (DOC) holders among the 13F filers tracked by SignalX were BlackRock ($1.7 billion), Vanguard Portfolio Management LLC ($1.2 billion), Vanguard Capital Management LLC ($902.3 million), State Street Corp ($887.0 million), JPMorgan Chase & Co ($477.4 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was DOC's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Healthpeak Properties (DOC) reported revenue of $604.0 million (up 6.2% from FY2024) and net income of $71.3 million. Diluted EPS was $0.10. The figures come from the XBRL data in the 10-K.

What are the main risks in DOC's latest 10-K?

In the 10-K filed February 3, 2026, Healthpeak Properties (DOC) flagged: U.S. federal policy shifts (NIH funding cuts, drug pricing, tariffs) creating life science tenant funding uncertainty, risking rent payment and expansion. Exposure to Medicare/Medicaid funding cuts and Affordable Care Act subsidy expiration impacting tenants in non-expansion states, affecting outpatient medical segment revenues. (AI summary of the Risk Factors section.)

What did DOC report in its latest 8-K?

Healthpeak Properties (DOC) filed an 8-K on November 2, 2026 reporting Item 7.01 (Regulation FD Disclosure) and Item 2.02 (Results of Operations and Financial Condition). Exhibit 99.2 contains Healthpeak’s supplemental financial results for the three and nine months ended September 30, 2026.

What are the latest DOC SEC filings?

Healthpeak Properties (DOC) filed its latest 10-K annual report on February 3, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 2, 2026 and a Form 4 insider filing on November 13, 2026.

What is DOC's SEC CIK number?

Healthpeak Properties (DOC)'s SEC Central Index Key (CIK) is 765880. EDGAR lists every DOC filing under that number.

Ask anything about DOC

The research agent reads DOC's filings, financials, insider trades and 13F holders, then answers with sources.